MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, December 27, 2014

British Columbia Agrees To fund AUBAGIO RRMS Therapy

December 26, 2014




GenzymeBritish Columbia’s PharmaCare drug program has announced that it will fund AUBAGIO, a therapy developed by Genzyme for the treatment of multiple sclerosis. AUBAGIO (teriflunomide) 14 mg has been officially added to PharmaCare’s provincial formulary as a first-line oral agent for patients suffering from relapsing remitting multiple sclerosis (RRMS).
As an immunomodulator with anti-inflammatory properties, AUBAGIO is specially indicated for RRMS and has been proven effective in the reduction and frequency of clinical exacerbations due to MS, as well as in delaying the progression of physical disability. The monotherapy was approved in Canada in November of last year, and even though its mechanism has not been completely understood, Aubagio is able to decrease the amount of activated lymphocytes in the central nervous system (CNS).
“We are pleased to have an additional therapy available to us in the treatment of MS. Having access to this new oral therapy will allow us to tailor our treatment to our patients’ needs. We are grateful to the provincial drug program in BC for approving access to this therapy in 1st line,” said Virginia Devonshire, who is a Clinical Assistant Professor Neurology at the UBC.
Genzyme’s development of AUBAGIO included a clinical program that involved more than 5,000 trial participants in 36 different countries. Moreover, the company has also studied the progression of patients who were treated in extension trials for up to 10 years, and the researchers demonstrated that the therapeutic’s benefits have extended throughout the duration of the treatment

~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT with MS Views and News - OPT-IN here


.
.


No comments: